Alvotadin

Quick links to important sections

Alvotadin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alvotadin

Property Description
Active ingredient Desloratadine
Forms Tablet, Oral Syrup, Orally Disintegrating Tablet (ODT)
Pharmacological class H₁-receptor Antagonist (Second-Generation Antihistamine)
Common purpose Relief from allergic inflammatory disorders
Origin Synthetic metabolite of Loratadine

What Type of Medicine is Alvotadin? (Classification and Origin)

Alvotadin is a medicinal preparation whose core component is the active substance Desloratadine, a synthetic compound classified as a Histamine H₁-receptor antagonist, which belongs to the class of antihistamines. This product is specifically grouped as a second-generation antihistamine, a designation confirming its targeted action outside the central nervous system. Desloratadine’s primary action involves providing symptomatic relief from allergic conditions, a core function associated with its pharmacological profile.

Desloratadine holds a key chemical distinction as the principal active metabolite of Loratadine, meaning it is the refined chemical form that the body produces to exert the majority of the anti-allergic effect. This synthetic origin and selective profile ensure the drug acts predominantly on peripheral receptors, mitigating potential systemic effects, such as notable drowsiness, often associated with older, first-generation compounds.


Active Composition and General Purpose

The active composition of Alvotadin centers exclusively on Desloratadine, confirming it as a single-entity product intended for highly specific therapeutic action. The overarching general purpose of this medication is to mitigate the discomfort and distress caused by the body's natural response to allergens, which underlies various allergic inflammatory disorders. A typical use scenario involves helping a patient manage chronic symptoms, such as the persistent itching associated with urticaria (hives).

This benefit is achieved through the compound's fundamental mechanism of selective H₁ receptor blocking. By occupying the peripheral H₁ receptors, Desloratadine blocks the action of the chemical mediator histamine, which is released by the body’s cells during allergic reactions. This mechanism is designed to reduce the clinical signs of the allergic response.


Available Forms of Alvotadin

Alvotadin is typically formulated for oral administration, utilizing different pharmaceutical preparations to provide suitable options for patients. A differentiating factor is its availability in an oral syrup form specifically tailored for pediatric and other patient groups who may have difficulty swallowing solid medication. These common dosage forms include the standard film-coated tablet, the oral syrup, and the orally disintegrating tablet (ODT). All formulations contain Desloratadine along with various pharmaceutical excipients—such as binders, fillers, and stabilizers—necessary for the stability and proper delivery of the active ingredient.

Regulatory References

  1. EMA Medicines Overview: Aerius (Desloratadine)

What side effects are possible with Alvotadin?

Possible side effects and safety information

Alvotadin (Desloratadine) adverse reactions are formally classified in regulatory documents based on frequency and the physiological system affected, providing a structured overview of the drug's safety profile.

Common and Reported Adverse Reactions

The safety profile is organized by frequency, using categories consistent with international regulatory standards. Common adverse reactions, observed in clinical trials at rates greater than or equal to placebo, typically include fatigue, dry mouth, and headache. Other frequently reported effects may include somnolence, pharyngitis, and myalgia.

System-Organ Classifications and Serious Events

Adverse reactions are grouped by System-Organ Class (SOC) in official labeling. These classes include Nervous System Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders. Rarely reported, but medically significant events are designated as Very Rare in regulatory documentation, including hypersensitivity reactions such as anaphylaxis and angioedema, as well as seizures, jaundice, and hepatitis.

Population-Specific Safety Statements

Official safety documents include considerations for specific patient groups. In the pediatric population (infants 6 to 23 months), fever, diarrhea, and upper respiratory tract infection were reported more frequently than placebo. Individuals with severe hepatic impairment or renal impairment should be managed with caution, as high plasma concentrations of desloratadine may occur. The medication is formally contraindicated in patients with a known hypersensitivity to desloratadine, any component of the formulation, or the parent compound, Loratadine.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile for Alvotadin (Desloratadine) primarily in the context of high-dose exposures where the magnitude of effects can be higher than those experienced with therapeutic doses. While clinical trials involving up to nine times the standard clinical dose showed no clinically relevant effects, documented manifestations associated with high exposures include somnolence (drowsiness) and headache. Post-marketing surveillance has also reported potential severe outcomes such as tachycardia and seizures.


Emergency Actions Mandated by Regulators

In the event of a suspected overdose, regulatory guidance requires users to call a doctor or get medical attention right away and contact the Poison Control Center immediately. This urgency is emphasized because no specific antidote is known for Desloratadine overdose.


Official Management and Monitoring

Management of an overdose is primarily symptomatic and supportive treatment. Healthcare professionals may consider standard measures to remove unabsorbed active substance (e.g., activated charcoal). Due to the potential for serious cardiac events associated with less-sedating antihistamines, cardiac monitoring may be required. Furthermore, regulatory documentation explicitly notes that Desloratadine is not eliminated by haemodialysis.

Therapeutic Uses of Alvotadin

Quick Facts

  • Support for managing: Symptoms of seasonal allergic rhinitis, including nasal and non-nasal discomfort.
  • Indicated for: Symptom relief associated with perennial allergic rhinitis.
  • Therapeutic use: Providing relief from itching (pruritus) and reducing hives (urticaria) associated with chronic idiopathic urticaria.

What Alvotadin Treats: Main Uses and Benefits

Alvotadin is a therapeutic agent used for the management of symptoms stemming from various allergic conditions. Its primary applications involve providing relief for both seasonal and perennial allergic rhinitis. For seasonal allergic rhinitis, this medication helps manage nasal symptoms like sneezing and runny nose, as well as non-nasal symptoms such as itchy, watery eyes.

In the context of perennial allergic rhinitis, which occurs year-round, Alvotadin is utilized to address the associated nasal and non-nasal discomfort. It is also an indicated treatment option for individuals dealing with chronic idiopathic urticaria (CIU), a skin condition characterized by hives with no clear cause. For CIU, the medication offers symptomatic relief by supporting the reduction of itching and the number and size of hives.

The therapeutic applications of this agent are intended to help improve the patient's overall quality of life by mitigating the effects of common allergy symptoms.

Eligibility and Restrictions for Use

The official regulatory criteria for Alvotadin (desloratadine) define who is eligible to use the medicine based on age, physiological status, and underlying health conditions.

Eligibility Classifications

Status Population Regulatory Context
Contraindicated Patients with known hypersensitivity to desloratadine, loratadine, or any formulation excipients.
Use Allowed Adults and adolescents aged 12 years and older. Children 6 months to 11 years (using specific forms like syrup).
Not Recommended Pregnant and breastfeeding women. Infants under 6 months (safety/efficacy not established).
Use with Caution Patients with severe hepatic or renal impairment (dose adjustment required). Individuals with a history of seizures.

Use is restricted in individuals with severe liver or kidney problems because the drug's exposure is significantly increased in these groups, necessitating a reduced, every-other-day administration in adults. Furthermore, tablet forms may contain lactose or aspartame (in ODTs), which are explicit contraindications for patients with specific hereditary metabolic conditions, such as Phenylketonuria (PKU) or rare sugar intolerances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alvotadin (Desloratadine) has been studied for potential interactions with various commonly used medicinal products, with the official regulatory profile focused on observed pharmacokinetic and pharmacodynamic effects.


Documented Pharmacokinetic Assessments

Clinical trials examined co-administration with several agents. Although increases in Desloratadine's exposure (Cmax and AUC) were observed, regulatory authorities concluded that these changes were not clinically relevant and do not typically require restriction.

Co-administered Substance Official Conclusion on Clinical Relevance
Ketoconazole (Antifungal) Not clinically relevant (Increased AUC/Cmax observed)
Erythromycin (Antibiotic) Not clinically relevant (Increased AUC/Cmax observed)
Azithromycin (Antibiotic) Not clinically relevant (No significant change in exposure)
Fluoxetine (Antidepressant) Not clinically relevant (No significant change in exposure)
Cimetidine (H₂-receptor Antagonist) Not clinically relevant (No significant change in exposure)

Alcohol and Food Interactions

In pharmacodynamic trials, taking Desloratadine with alcohol did not potentiate the alcohol-induced impairment of performance. However, caution is advised based on post-marketing reports of alcohol intolerance. Alvotadin may be taken with or without food, as meals do not affect its clinical efficacy.

Population-Specific Interaction Notes

Caution is officially advised for use in patients with severe hepatic impairment or severe renal insufficiency. Furthermore, caution is recommended for patients with a personal or familial history of seizures, especially in young children.

Mechanism of Action

Selective H1 -Receptor Inverse Agonism

The drug's primary action is highly targeted: it functions as a selective inverse agonist at the peripheral Histamine H1 -receptor. This molecular interaction actively reduces the receptor’s baseline signaling and modulates the signaling of histamine released during the body's allergic response. This direct blockade of the mediator pathway results in the inhibition of histamine-induced vascular permeability and the reduction of sensory nerve ending stimulation.

Modulation of the Inflammatory Cascade

Beyond immediate receptor blockade, Desloratadine engages a secondary mechanism that influences sustained inflammatory processes. This includes modulating key transcription factors like NF-kappaB, which regulate the generation of pro-inflammatory mediators such as certain cytokines and chemokines. By limiting the synthesis of these chemical messengers, this effect subsequently limits the directed movement and infiltration of inflammatory cells, such as eosinophils, within the affected tissues.

Functional Peripheral Selectivity

The molecule exhibits peripheral selectivity due to its limited capacity to traverse the blood-brain barrier; it primarily engages H1 -receptors outside the central nervous system (CNS). This functional attribute results in low H1 -receptor occupancy in the CNS; the central histamine pathways, which are critical for the sleep/wake cycle and arousal, remain largely unaffected by the peripheral receptor blockade.

Dosage and Administration Information

How to Use Alvotadin

Alvotadin (Desloratadine) is a medicinal agent administered exclusively via the oral route for all approved forms. The dosing principles are based on a fixed concentration and frequency, with adjustments necessary only for specific populations or formulations.


Standard Dosing and Frequency

The standard regimen for adults and adolescents (12 years and older) is 5 mg once daily. This once-daily schedule is utilized to achieve the intended continuous effect over a 24-hour period. Treatment duration is typically determined by the nature of the condition; for intermittent allergic rhinitis, use can be discontinued when symptoms resolve and resumed upon reappearance, while persistent symptoms may necessitate continued use.

Age Group Standard Daily Dose (Oral)
Adults and Adolescents (ge 12 years) 5 mg once daily
Children 6–11 years 2.5 mg once daily
Children 12 months–5 years 1.25 mg once daily

Administration Context and Adjustments

Alvotadin may be taken without regard to meals (with or without food). For liquid formulations, such as the oral syrup, the dose must be measured accurately using a calibrated device. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to resume the regular once-daily schedule.

Adult patients with confirmed hepatic or renal impairment require a modification of the standard schedule; the recommended starting dose for these individuals is 5 mg every other day to mitigate increased drug exposure.

Recent Clinical Evidence

Evidence for Allergic Rhinitis (Seasonal and Year-Round Allergies)

Research for Alvotadin was studied for both seasonal and year-round allergic rhinitis, conditions characterized by fluctuating or episodic manifestations. The research primarily consists of short-term Randomized Controlled Trials (RCTs). These studies research examined how patient-reported outcomes describing perceived discomfort changed, often through total symptom scores (TSS), as well as outcomes reflecting daily functioning or activity level. The findings describe patterns observed in the studies where Alvotadin was associated with changes in these outcomes compared to a placebo. Follow-up durations were limited in many of these core studies, meaning the data primarily contributes to understanding symptom patterns over defined time intervals.


Evidence for Chronic Hives (Chronic Urticaria)

Alvotadin was evaluated in studies for chronic hives, which are conditions involving periods of heightened symptoms and flare-ups. The research explored how this compound influenced outcomes related to physical discomfort, specifically itching severity and the count and size of hives (wheals). Findings indicate that when Alvotadin was studied for chronic hives, a change was observed in these symptom measures in the studied populations compared to placebo. The majority of the research had limited follow-up durations, meaning there is limited information for long-term outcomes regarding the management of conditions presenting with cycles of stability and flare-ups.


Long-Term Evidence, Special Populations, and Research Gaps

Research across both indications primarily focuses on short-term efficacy, and long-term effects are not fully established. Evidence is limited regarding continuous use over many months or years.

Studies was studied for use in children as young as two years of age; however, sample sizes were modest in some pediatric trials. Alvotadin was observed in studies involving adults with pre-existing kidney or liver conditions. Findings indicate that exposure to the compound may be greater in individuals with reduced function. Because this observation was associated with differences in how the compound is processed, these differences are associated with the need for special consideration for individuals with severe kidney or liver impairment. The overall evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials

Frequently Asked Questions (FAQ)

Common questions about Alvotadin (FAQ)

Q: Do I need a prescription to get Alvotadin?

The regulatory status of Alvotadin (desloratadine) varies depending on the country or regulatory authority. In some areas, it is classified as a prescription-only medicine, while in others, it may be available over-the-counter (OTC). The required classification is determined by the specific governing health body in that region.

Q: Is Alvotadin a steroid?

No, Alvotadin is not classified as a steroid. Official regulatory information identifies the active ingredient, desloratadine, as a second-generation Histamine H₁-receptor antagonist. This means it is an antihistamine that works by targeting the histamine response.

Q: Is Alvotadin safe to use for a long period of time?

Official research evidence primarily focuses on the short-term use of Alvotadin for controlling allergy symptoms. Regulatory documents note that specific information regarding the effects of continuous use over many months or years is limited or not fully established. Regulatory documents suggest continuous use should be managed by a healthcare provider.

Q: Can women who are planning pregnancy use Alvotadin?

Official labeling states there is no data available on human infertility associated with Alvotadin. Use is generally not recommended once a woman is pregnant. Official information indicates that caution is generally recommended for those planning pregnancy.

Q: What is the purpose of the inactive ingredients in Alvotadin tablets?

Inactive ingredients, known as excipients, are included for pharmaceutical purposes. They do not have a therapeutic effect but help maintain the drug's stability, give the tablet its structure, and control the delivery of the active substance within the body. Their roles are vital for the product's function.

Q: Is Alvotadin suitable for individuals with lactose intolerance?

The tablet formulation of Alvotadin may contain lactose, which makes it unsuitable for individuals with specific hereditary sugar intolerances. Other formulations, such as the oral syrup or orally disintegrating tablet (ODT), list different inactive ingredients. The specific form chosen may depend on individual needs.

Q: Are there specific tests a doctor might perform before prescribing Alvotadin?

Official warnings advise caution for use in patients with severe hepatic (liver) or renal (kidney) impairment due to increased drug exposure in these cases. The warnings state that the prescribed administration schedule should be adjusted for severe kidney or liver impairment.

Q: Can Alvotadin be taken on an empty stomach?

Yes, Alvotadin may be taken without regard to meals. Official product information states that food does not affect the absorption of the medicine, meaning its efficacy remains the same whether it is taken with or without food.

Q: Are there any major diet restrictions while taking Alvotadin?

Official labeling allows the medication to be taken with or without food. Regulatory documents do not list any major dietary restrictions, though information regarding alcohol consumption is included in the product safety profile.

Q: Why do people sometimes feel tired after taking Alvotadin?

Although Alvotadin is considered non-sedating because it has limited entry into the central nervous system, fatigue is listed as a common adverse reaction in clinical studies. Official information indicates that, despite its selective action, this feeling of tiredness can occur.

Q: Can Alvotadin affect my sleep?

Studies and official information indicate that Alvotadin is peripherally selective and has limited entry into the central nervous system (CNS). Because it minimally engages the CNS, it is not expected to interfere significantly with the central histamine pathways that regulate the sleep/wake cycle.

Q: What common over-the-counter pain relievers can interact with Alvotadin?

The official regulatory interaction profile for Alvotadin primarily focuses on a limited number of prescription drugs. Common over-the-counter pain relievers (such as paracetamol or ibuprofen) are generally not listed as having clinically relevant interactions in these specific regulatory documents.

Q: Is it okay to drive while taking Alvotadin?

Clinical studies indicate that Alvotadin has negligible influence on the ability to drive and use machines. However, individual responses to any medication can vary, and official advice includes establishing the individual's response to the medicine before engaging in activities requiring full mental alertness.

Q: Is it true that Alvotadin can be used for things other than its primary approved use?

Alvotadin is officially approved and indicated for the relief of symptoms associated with allergic rhinitis (inflammation of the nasal passages) and chronic urticaria (hives). Regulatory approval strictly limits the use of the drug to these specific, established medical conditions.

Q: Can Alvotadin cause stomach upset?

Official safety documents list Gastrointestinal Disorders as a System-Organ Class for adverse reactions. Nausea and general stomach upset have been reported in some clinical trials as common side effects of Alvotadin.

Q: Is it possible to be allergic to Alvotadin?

Yes, it is possible. Official labeling states that hypersensitivity reactions—the medical term for severe allergic reactions—have been reported in rare cases. These reactions can include rash, swelling, or anaphylaxis. A known hypersensitivity to the drug is listed as a contraindication.

Q: Why is Alvotadin sometimes used for conditions that seem unrelated to its main purpose?

The regulatory approvals for Alvotadin are strictly limited to the treatment of allergic rhinitis and chronic urticaria (hives). Information on its use for conditions outside of these established indications is not supported by official labeling.

Q: Are there any known food-drug interactions with Alvotadin?

Official studies confirm that Alvotadin may be taken with or without food, as meals do not affect its absorption or clinical efficacy. Regulatory documents do not list interactions with specific foods, vitamins, or nutritional supplements other than alcohol.

Q: How long does Alvotadin stay in your system?

Regulatory pharmacokinetic data reports that the elimination plasma half-life for the active substance is approximately 20 to 30 hours in most people. This half-life is the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Is it normal for the effect of Alvotadin to change over time?

Studies focusing on different patient groups, such as older adults, have observed minor changes in how the drug is processed by the body over time. However, regulatory documents state that these changes are not considered to be clinically relevant and do not typically require a dosage adjustment.

How should Alvotadin be stored and disposed of?

Storage and Disposal Requirements for Alvotadin (Desloratadine)

Official regulatory labeling dictates strict conditions to maintain the stability and safety of Alvotadin, which contains Desloratadine.

Storage Conditions

Alvotadin tablets and oral solution must be stored at controlled room temperature, generally defined as below 30 C. The product must be protected from moisture and should be kept in its original container.

Requirement Specific Condition
Temperature Restriction Do not freeze (especially oral solution).
Child Safety Keep out of the sight and reach of children.
In-Use Stability Oral solution must be used within two months of first opening.

Disposal

Unused or expired Alvotadin must not be disposed of via household waste or wastewater. Disposal must be carried out according to local requirements, typically by returning the product to a pharmacist or designated pharmaceutical take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alvotadin found in:

A-Z Index: